Navigation Links
D-Pharm Secures Funding From Israel's Chief Scientist's Office
Date:4/6/2008

REHOVOT, Israel, April 7 /PRNewswire/ -- D-Pharm announced today that it received notice from Israel's Chief Scientist's Office (CSO) of its commitment to match expenditures on four of D-Pharm's R&D programs with a total grant of up to NIS 11 million (over $3 million).

Alex Kozak, PhD, CEO and President of D-Pharm, said "We are grateful to the CSO for this vote of confidence and its firm support over the years, from the time of the company's inception as a technological incubator. The CSO's backing has helped us to build a robust pipeline with two advanced clinical stage products in stroke (DP-b99) and epilepsy and migraine (DP-VPA) followed by an exciting range of preclinical developments in Alzheimer's disease, cancer and psoriasis".

D-Pharm's drug-development programs emerged from the company's unique platform technology of lipid-like medicine. The CSO grant supports four major company developments: GMP production of DP-b99 in-house, IND preparations and initiation of a pivotal Phase III trial in stroke patients; a Phase II migraine study of DP-VPA in Israeli medical centers; and two preclinical programs, DP-460 for Alzheimer's disease and LipidoMimetix for cancer.

The Chief Scientist's Office has supported D-Pharm since its establishment, providing grants of about $18 million, excluding this latest announcement.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. D-Pharm recently received Israeli health ministry approval to commence a Phase II study of DP-VPA in migraine patients. DP-460 is i
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. Aerovance Secures $20 Million in Debt Financing
3. Amarin Secures Global Intellectual Property Rights for Lipid Programs
4. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
5. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
6. Taligen Therapeutics Secures Series B Financing
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Dendreon Secures $130 Million Committed Equity Financing Facility
9. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...er 30, 2009 An international team of applied scie...Zrich have demonstrated compact, multibeam, and mu...rt of the light spectrum (infrared). By contrast, ...defined wavelength. The innovative multibeam laser...mote chemical sensing pollution monitoring, optica...
(Date:11/30/2009)...F MANOR, N.Y., Nov. 30 Good Public...or the publication of company-sponsored medical re...tish Medical Journal (BMJ). "The publication of GP...of providing support and guidance for industry spo...ts in the peer-reviewed medical literature," said ...
(Date:11/30/2009)...Nov. 30 BioMarin Pharmac... the Food and Drug Administration (FDA) has grante...(3,4-DAP), amifampridine phosphate, for the rare a...e (LEMS). 3,4-DAP has previously received orphan ...9, the Committee for Medicinal Products for Human ...
(Date:11/30/2009)...NDON, November 30 ApaTech, the rap...ope,s fastest growing,Biotech/Pharmaceutical/Medic...09 Technology Fast 500 for EMEA (Europe, Middle Ea...based on a companies, five-year revenue growth,fo... this period. This,achievement places ApaTech 9th ...
Breaking Biology Technology:Scientists demonstrate multibeam, multi-functional lasers 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
...7 The market for congestive heart,failure (CHF) d...7, and is,expected to reach $30 billion by 2017, a...Congestive Heart Failure: Major World Markets, Vol...driven by three factors: an,increased incidence of...n,search of targeted therapies which is creating o...
...ril 17 Spherix Incorporated,(Nasdaq: SPEX ) anno...perations. Mr. Brown will be monitoring and overse...rial regarding the use of Naturlose(R) as a,treatm...as allowed Spherix,to terminate its agreement with...r full control of the clinical trial and its pivot...
...7 SPO Medical Inc. (OTC:,SPOM), a leading develop...r,use in portable monitoring devices, today announ...Capital Ventures (ACV), a leading provider of,comp... cap community, as an,investor relations consultan...ve Officer of SPO Medical,commented, "As we contin...
Other Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Spherix Hires Key Employees 2SPO Medical Retains American Capital Ventures for Investor Relations Services 2SPO Medical Retains American Capital Ventures for Investor Relations Services 3
(Date:11/26/2009)...ies has shown that closing schools in the event of...ficant role in reducing illness transmission. Rese...fectious Diseases compared opportunities for infe...g that they were reduced when schools are shut. ,...Belgium, led a team of European researchers in usi...
(Date:11/25/2009)...ay be used to boost resistance to, or slow, the de...edicine researchers report in a study published in..., Parkinson,s disease is caused by a degeneratio...nown as the substantia nigra, which is responsible...opamine in late-stage Parkinson,s causes symptoms ...
(Date:11/25/2009)...s some 250 million liters of blood through the bod...he heart have to be extremely durable. The researc...ir of the Department of Medicine III at Heidelberg...tus), has discovered a protein that is responsible...the sarcomere. In cooperation with other researche...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 1Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 9GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 1GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 2GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 3Opto electronic nose sniffs out toxic gases 9902 1Opto electronic nose sniffs out toxic gases 9902 2Opto electronic nose sniffs out toxic gases 9902 3
...ghting like a girl or fighting like a boy is hardw...in the Nov. 19 Nature Neuroscience advance online ...l School and the Institute of Molecular Pathology ...s "fruitless" is a key factor underlying sexual di...ne in an unlikely new animal model for understandi...
...e Shoklo Malaria Research Unit (SMRU), Thailand, w...28 December entitled "Twenty Years of Malaria Rese...nationally-renowned experts and featuring talks an...a, from epidemiology to therapeutics and from immu...Research Unit (SMRU) in Mae Sot, Thailand, which b...
...searchers at the Albert Einstein College of Medici...n grant from the National Cancer Institute to stud...t with surrounding tissues, cells and chemicals in... invade other areas of the body in the process kno...ohn Condeelis, co-chair of anatomy and structural ...
Other Biology News:Fighting like a girl or boy determined by gene in fruit flies 2Fighting like a girl or boy determined by gene in fruit flies 3Twenty Years of Malaria Research: Outcomes and Perspectives 2World's smallest cancer detection device 2
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...r routine procedures. Hollandes contains formaldeh...l decalcify small bone specimens. Tissue that is f...ith most stains, and the cupric acetate in the sol...nophil and endocrine cell granules so that less ly...
...tograph/Mass Spectrometer, utilizing many of the h...igh throughput and excellent productivity, providi...io. Like the GCMS-QP2010 Plus, the GCMS-QP2010s fe...um separation, 20 temperature ramps, and both scan...
Biology Products: